More than half of novel drug approvals were based on single studies in 2022
Regulatory NewsMary Ellen Schneider
BiologicsClinical TrialsNorth AmericaPharmaceuticalsRegulatory NewsMary Ellen SchneiderBiologicsClinical TrialsNorth AmericaPharmaceuticals